NeuroMetrix (NSDQ:NURO) shares saw a huge boost this today on strong second-quarter revenues and an increased bottom line. NURO shares were up 19.1% at $24.77 per share in mid-afternoon trading. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — was up 0.4%. The Woburn, Mass.-based company posted losses […]
Neurometrix
NeuroMetrix stock skyrockets on news of FDA breakthrough device designation
NeuroMetrix (NSDQ:NURO) today announced that its Quell device has received FDA breakthrough designation for treating fibromyalgia symptoms in adults. The news saw NURO shares nearly triple in value to $9.72 apiece near the close of trading. MassDevice‘s MedTech 100 Index, which includes stocks of the world’s largest medical device companies, was up 1.5%. Fibromyalgia involves the […]
NeuroMetrix reports mixed results in fibromyalgia trial
NeuroMetrix (NSDQ:NURO) announced a mixed bag of top-line results from its trial of Quell in patients with fibromyalgia. Woburn, Mass.–based NeuroMetrix’s double-blind, randomized, sham-controlled trial evaluated the treatment of fibromyalgia with Quell, an over-the-counter novel transcutaneous electrical nerve stimulator (TENS) indicated for symptomatic relief and management of chronic lower extremity pain. Quell, a wearable device […]
NeuroMetrix slides on Q4 losses
NeuroMetrix (NSDQ:NURO) shares dipped today on fourth-quarter results that showcased losses despite an improved bottom line. The Woburn, Mass.-based company posted losses of -$325,767 on sales of $1.8 million for the three months ended Dec. 31, 2020, for a 69.2% bottom-line gain on sales growth of 6%. NeuroMetrix experienced headwinds from the COVID-19 pandemic and felt […]
NeuroMetrix launches Quell app for Apple Watch
NeuroMetrix (NSDQ:NURO) announced that it launched the Quell Watch App for transcutaneous electrical nerve stimulation (TENS). Woburn, Mass.-based NeuroMetrix’s Quell app, which is now available for download from the Apple App Store, allows users of the Quell system to personalize and manage their therapy discreetly on iPhone and Android smartphones, according to a news release. Quell […]
FTC to refund Neurometrix consumers $3.9M in false ad case
The Federal Trade Commission announced that it is refunding NeuroMetrix (NSDQ:NURO) consumers nearly $3.9 million after false advertising. NeuroMetrix marketed its Quell transcutaneous electrical nerve stimulation device as a clinically proven and FDA-cleared treatment for widespread chronic pain relief when placed below the knee, according to the FTC, which said that the company lacks scientific evidence […]
MedTech 100 roundup: Industry remains on the rise
The medtech industry continues to climb back up in the markets, following a landmark week with another move up toward its pre-COVID-19-pandemic highs. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — sat at 89.29 points at the end of last week (July 24). That total represents just a […]
NeuroMetrix improves bottom line despite nearly halved Q2 sales
NeuroMetrix (NSDQ:NURO) shares dipped today after posting second-quarter results that reflected the effects of the COVID-19 pandemic. The Woburn, Mass.-based pain-treating transcutaneous electrical nerve stimulation (TENS) device developer posted losses of -$851,944 on sales of $$1.4 million for the three months ended June 30, 2020, for a 74.7% bottom-line gain on a sales decline of 42.2%. […]
MedTech 100 roundup: Medtech stocks hit highest point since early March
Medtech stocks generally ended last week at their highest point in more than a month — even as the COVID-19 pandemic continues to cause economic havoc. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — sat at 82.3 points at the end of last week (April 24). That […]
NeuroMetrix dips on Q1 losses
NeuroMetrix (NSDQ:NURO) shares fell today on first-quarter losses that reflected the impact of COVID-19 on its business. The Woburn, Mass.-based pain-treating transcutaneous electrical nerve stimulation (TENS) device developer posted losses of -$657,371 on sales of $2.2 million for the three months ended March 31, 2020, seeing its bottom line slide into the red from profits of […]
NeuroMetrix settles $4m false advertising case with FTC
Pain-treating TENS device company NeuroMetrix (NSDQ:NURO) has agreed to pay at least $4 million to settle a false advertising case brought by the Federal Trade Commission FTC. The commission said today that the Woburn, Mass.-based company also agreed to stop making deceptive claims that its Quell device treats pain throughout the body when placed below the […]